You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
260 Chua et al.<br />
12. Valmori, D., Dutoit, V., Ayyoub, M., et al. (2003) Simultaneous CD8+ T cell<br />
responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.<br />
Cancer Immun. 3, 15.<br />
13. Noguchi, M., Itoh, K., Suekane, S., et al. (2004) Phase I trial of patient-oriented<br />
vaccination in HLA-A2-positive patients with metastatic hormone-refractory<br />
prostate cancer. Cancer Sci. 95(1), 77–84.<br />
14. Chianese-Bullock, K.A., Pressley, J., Garbee, C., et al. (2005) MAGE-A1-,<br />
MAGE-A10-, and gp100-derived peptides are immunogenic when combined with<br />
granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant<br />
and administered as part of a multipeptide vaccine for melanoma. J. Immunol.<br />
174(5), 3080–3086.<br />
15. Ghosh, S. and Jackson, D.C. (1999) Antigenic and immunogenic properties<br />
of totally synthetic peptide-based anti-fertility vaccines. Int. Immunol. 11(7),<br />
1103–1110.<br />
16. Ferro, V.A., Khan, M.A., McAdam, D., et al. (2004) Efficacy of an anti-fertility<br />
vaccine based on mammalian gonadotrophin releasing hormone (GnRH-I)—a histological<br />
comparison in male animals. Vet. Immunol. Immunopathol. 101(1–2), 73–86.<br />
17. Zeng, W., Ghosh, S., Macris, M., Pagnon, J., and Jackson, D.C. (2001) Assembly<br />
of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of<br />
different chemical linkages and epitope orientations on biological activity. Vaccine<br />
19(28–29), 3843–3852.<br />
18. Jinshu, X., Jingjing, L., Duan, P., et al. (2005) A synthetic gonadotropin-releasing<br />
hormone (GnRH) vaccine for control of fertility and hormone dependent diseases<br />
without any adjuvant. Vaccine 23(40), 4834–4843.<br />
19. Mesa, C. and Fernandez, L.E. (2004) Challenges facing adjuvants for cancer<br />
immunotherapy. Immunol. Cell Biol. 82(6), 644–650.<br />
20. Pashine, A., Valiante, N.M., and Ulmer, J.B. (2005) Targeting the innate immune<br />
response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl), S63–68.<br />
21. BenMohamed, L., Belkaid, Y., Loing, E., Brahimi, K., Gras-Masse, H., and<br />
Druilhe, P. (2002) Systemic immune responses induced by mucosal administration<br />
of lipopeptides without adjuvant. Eur. J. Immunol. 32(8), 2274–2281.<br />
22. Le Gal, F.A., Prevost-Blondel, A., Lengagne, R., et al. (2002) Lipopeptide-based<br />
melanoma cancer vaccine induced a strong MART-27–35-cytotoxic T lymphocyte<br />
response in a preclinal study. Int. J. Cancer 98(2), 221–227.<br />
23. Chua, B.Y., Healy, A., Cameron, P.U., et al. (2003) Maturation of dendritic cells<br />
with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol.<br />
Cell Biol. 81(1), 67–72.<br />
24. Muhlradt, P.F., Kiess, M., Meyer, H., Sussmuth, R., and Jung, G. (1997) Isolation,<br />
structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from<br />
Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185(11),<br />
1951–1958.<br />
25. Zeng, W., Ghosh, S., Lau, Y.F., Brown, L.E., and Jackson, D.C. (2002) Highly<br />
immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive<br />
vaccines. J. Immunol. 169(9), 4905–4912.
Change language